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C
ompared with our ancestors, Western societies today lead a lifestyle that is much more
sedentary, probably as a result of cultural changes stemming from modern socio-economic
morays. Taking into account differences in body size, our energy expenditure per kilogram of
body weight has been estimated to be ,40% of that of our prehistoric ancestors.1 Current estimates
suggest that 7 out of 10 adults are inactive or lack adequate conditioning,2 and this lack of adequate
exercise, combined with dietary indiscretion, has contributed to the worldwide epidemic of obesity
and non-alcoholic fatty liver disease (NAFLD). Within the USA, data suggest that 64.5% of the adult
population is now overweight or obese, with a worldwide prevalence of 40–60%.3–5 Obesity, combined
with host factors such as diet, sedentary lifestyle and genetic predisposition, has been directly
associated with increases in the prevalence of insulin resistance, diabetes mellitus and the metabolic
syndrome. The hepatic manifestation of the metabolic syndrome, NAFLD, has also increased in
prevalence, now considered to be around 20–30% in Western countries. Among morbidly obese
patients undergoing bariatric surgery, approximately 90% have NAFLD and 36–37% have the more
aggressive form of fatty liver, non-alcoholic steatohepatitis (NASH).6 7 In patients with NAFLD,
advancing age, increasing weight, the number of features of the metabolic syndrome and the degree
of insulin resistance have all been independently associated with NASH severity.8 Evidence-based
treatment options for NAFLD are currently lacking. Recent data suggest that the thiazolidinedione
class of insulin sensitisers may be efficacious, but widespread utilisation of these agents awaits
further investigation.9 Evidence also supports a role for weight loss, achieved through diet and
exercise.
The purpose of this review is to describe the currently accepted pathophysiology of NAFLD, to
highlight the known dietary and exercise habits of patients with NAFLD, and to detail the benefits of
lifestyle modification with diet and/or exercise on parameters of metabolic syndrome, including
insulin resistance and NAFLD. The effects on liver histopathology, where available, will also be
detailed.
PATHOPHYSIOLOGY OF NAFLDc
The majority of NAFLD patients are overweight or obese and have underlying insulin, and probably
leptin, resistance that results in dysregulated energy metabolism. The regulation of glucose and lipid
metabolism involves a complex interplay between adipose tissue, skeletal muscle and the liver. While
our knowledge of the pathogenesis of hepatic steatosis has undoubtedly increased over the last
decade, many uncertainties remain, and it remains the subject of intense investigation. Hepatic
steatosis derives from several possible sources including: (1) increased free fatty acid (FFA) delivery
to the liver as a result of dietary fat intake and increased lipolysis within insulin-resistant adipose
tissue; (2) increased hepatic de novo lipogenesis (DNL); (3) decreased FFA oxidation; and (4)
decreased triacylglycerol (TAG) export from the liver in the form of very low-density lipoprotein
(VLDL). The largest contributor to hepatic steatosis in patients with NAFLD is increased FFA influx to
the liver (60%), followed by DNL (,26%).10
Increased hepatic l ipid supply
In insulin-resistant states, principally obesity and type 2 diabetes, adipose tissue hormone-sensitive
lipase activity is not fully suppressed by insulin, resulting in enhanced lipolysis and non-esterified
fatty acid (NEFA) flux into the systemic circulation (fig 1). The precise mechanism of adipocyte
insulin resistance in obesity remains a subject of controversy, but an emerging body of data suggest
that an altered adipocytokine milieu in visceral fat resulting from macrophage infiltration is
important.11 This milieu is characterised by increased expression of pro-inflammatory cytokines, such
as tumour necrosis factor a (TNFa) and interleukin 6 (IL6), that can directly inhibit insulin
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signalling, and decreased expression of adiponectin, an anti-
steatotic, and insulin-sensitising adipocyte-derived cytokine
(adipocytokine) in both skeletal muscle and liver.12
Hepatic lipid synthesis and oxidation
Energy metabolism within the liver is tightly regulated. Two
transcription factors, sterol regulatory element-binding protein
(SREBP-1) and carbohydrate response element-binding protein
(ChREBP), are intimately involved in hepatic glucose and lipid
metabolism, and their activity is increased in animal models of
NAFLD.13 14 The former is induced by insulin and high-fat diets,
and regulates glycolytic and lipogenic gene expression resulting
in increased DNL and a concomitant decrease in FFA oxidation
resulting from malonyl-CoA-induced inhibition of carnitine
palmitoyl transferase (CPT)-1 reducing mitochondrial FFA
uptake.15 ChREBP exerts similar effects on glycolytic and
lipogenic gene expression and also increases the expression of
genes involved in triglyceride synthesis. In contrast to SREBP-1,
ChREBP is up-regulated by glucose, which increases its nuclear
translocation and its DNA binding/transcriptional activity.16
Inhibition of ChREBP in ob/ob leptin-deficient mice reduces
hepatic steatosis by decreasing lipogenesis and enhancing FFA
b-oxidation, with a concomitant decrease in circulating plasma
triglycerides and FFA resulting in the restoration of hepatic,
skeletal muscle and adipose tissue insulin sensitivity.14 This
study provides further evidence linking fat accumulation to
insulin resistance in both hepatic and non-hepatic tissues,
principally skeletal muscle.17 18
Insulin resistance
Skeletal muscle is the primary site for glucose disposal via
insulin-dependent pathways, accounting for about 75% of
whole-body insulin-stimulated glucose uptake.19 Insulin bind-
ing to the insulin receptor on the myocyte plasma membrane
results in autophosphorylation of the receptor, allowing insulin
receptor substrate (IRS)-1 adaptor protein to bind and undergo
tyrosine phosphorylation (fig 2A). IRS-1-associated phosphati-
dylinositol 3-kinase (PI3K) activity is increased, which results
in downstream activation of Akt/PKB, leading to enhanced
glucose uptake into the cell, via increased GLUT-4 translocation
from the cytosol to the cell membrane, and up-regulation of
glycogen synthesis and glucose oxidation.18 In obese indivi-
duals, there is reduced insulin-stimulated glucose disposal in
skeletal muscle, most probably due to increased intramyocel-
lular lipid content (fig 2B).18 The increased concentration of
FFA (or more probably their esterification product, diacylgly-
cerol (DAG), activates the serine/threonine kinase PKCh which
phosphorylates IRS-1 on critical serine sites, thereby inhibiting
Figure 1 Mechanisms for development
of fatty liver in the setting of insulin
resistance. In the setting of insulin
resistance, there is increased adipose
tissue hormone-sensitive lipase activity
that results in enhanced lipolysis and
increased non-esterified fatty acid
(NEFA) delivery to the liver. NEFAs are
preferentially esterified to triglycerides.
Additionally, hyperinsulinaemia leads to
increased sterol regulatory element-
binding protein (SREBP) expression,
resulting in increased de novo
lipogenesis (DNL) and decreased fatty
acid oxidation. Carbohydrate response
element-binding protein (ChREBP) is
induced by hyperglycaemia and leads
to further increases in DNL. Decreased
hepatic lipid transport may also occur,
in part via altered synthesis of
apolipoprotein B, leading to decreased
very low-density lipoprotein (VLDL)
production.
Figure 2 Mechanisms for free fatty acid (FFA)-induced skeletal muscle
insulin resistance. (A) Normal glucose uptake into skeletal muscle occurs
via binding of insulin to the insulin receptor, resulting in receptor
autophosporylation and subsequent binding and tyrosine phosporylation
of insulin receptor substrate (IRS)-1. Subsequently, phosphatidylinositol 3-
kinase (PI3K) is activated and results in downstream activation of Akt,
leading to GLUT-4 translocation to the myocyte plasma membrane and
glucose uptake into the cell. (B) Increased intramyocellular lipid content
leads to the activation of protein kinase Ch (PKCh) which results in serine
phosporylation of IRS-1, thereby inhibiting its tyrosine phosphorylation.
This prevents the activation of PI3K and GLUT-4 translocation to the cell
surface. Thus glucose entry into the cell is inhibited. AMPK, AMP-activated
protein kinase; DAG, diacylglycerol.
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its tyrosine phosphorylation and subsequently the activation of
PI3K and the resulting glucose uptake, glycogen synthesis and
glycolysis. Other cytokine-regulated serine/threonine kinases
including IkB kinase-b (IKKb) and JNK-1 may also be involved
since the inhibition of IKKb via exercise20 or salicylates results
in improved insulin sensitivity.21 As discussed above, the
hyperglycaemia resulting from skeletal muscle insulin resis-
tance in obesity, will, via activation of ChREBP, lead to
increased hepatic fat synthesis, reduced fat oxidation and
steatosis. Moreover, the accumulation of FFA/DAG in the liver
results in hepatic insulin resistance, via PKCe-induced IRS-2
serine phosphorylation, which, reduces insulin’s inhibitory
effect on gluconeogenesis, contributing further to hyperglycae-
mia.18 22
Leptin resistance
Lack of response to the adipocytokine leptin (leptin resistance)
rather than insulin resistance may be an important factor in the
pathogenesis of hepatic steatosis. The evidence for leptin
resistance in NAFLD, though indirect, is compelling. Leptin
exerts a number of anti-steatotic effects on the liver, including
inhibition of lipid synthesis via reduced expression of stearoyl
CoA desaturase (SCD)-123 and enhanced FFA oxidation, via up-
regulation of peroxisome proliferator-activated receptor a
(PPARa),24 and yet patients with NAFLD have increased serum
leptin concentrations.25 Recent studies in genetically leptin-
resistant (ZDF) rats have dissociated the direct anti-steatotic
effects of leptin from any indirect effects via improved hepatic
insulin sensitivity.26 The mechanism of leptin resistance in
obesity is unclear; however, it may be enhanced by the
ingestion of fructose which leads to an inhibition of STAT-3,
abrogating leptin-mediated PPARa activation resulting in
decreased fatty acid oxidation, increased SREBP-1 expression
and increased hepatic triglyceride content.27 Further inhibition
of STAT-3 may occur as a result of up-regulation of suppressor
of cytokine signalling-3 (SOCS-3) by adipose tissue or
hepatocyte-derived inflammatory cytokines.15 28
AMP-activated protein kinase
Of particular relevance to the therapy of NAFLD, AMP-
activated protein kinase (AMPK) has recently emerged as a
key orchestrator of both hormonal and non-hormonal regula-
tors of energy metabolism in liver, skeletal muscle and adipose
tissue. Activated by an increase in the AMP/ATP ratio, AMPK
activity is enhanced by physiological processes that induce
metabolic stress and either decrease ATP production (ischae-
mia, hypoxia) or increase its consumption (exercise).29 Once
activated, AMPK acts to increase ATP-generating cellular events
while turning off energy-consuming processes to restore energy
balance. In the liver, the activation of AMPK by starvation,
exercise,30 adiponectin,31 leptin (via inhibition of SCD-1), the
biguanide metformin32 or the thiazolidinedione class of insulin
sensitisers33 suppresses expression of SREBP-1,34 ChREBP,35 and
acetyl-CoA carboxylase (ACC),36 resulting in decreased DNL
and increased FFA oxidation. Hepatic gluconeogenesis is also
inhibited. Within skeletal muscle, exercise, leptin or drug-
related AMPK activation enhances glucose uptake via direct
non-insulin-dependent GLUT-4 translocation, and increases
pyruvate oxidation.32 In adipose tissue, hormone-sensitive
lipase activation is suppressed, resulting in decreased lipolysis.32
Decreased hepatic lipid export
Hepatic fat, in the form of TAG-rich VLDL, can be transported
out of the liver. This occurs, in part, via microsomal triglyceride
transfer protein (MTP)-mediated TAG association with apoli-
poprotein B (ApoB). Inhibition of MTP in mice results in
inefficient lipidation of ApoB, leading to a lack of TAG transfer
out of the liver.37 Hyperinsulinaemia can alter the synthesis of
ApoB, leading to decreased VLDL production,38 and hyperinsu-
linaemic NASH patients have been reported to have impaired
synthesis of ApoB, almost certainly contributing to hepatic fat
accumulation.39
Inflammation and fibrosis
The precise mechanisms leading to inflammation and sub-
sequent fibrosis in NAFLD are far less clear than those involved
in steatosis; however, most available evidence suggests that
many of the factors contributing to fat accumulation also play a
role in progressive disease.40 This implies that any lifestyle
modifications aimed at reducing steatosis should also improve
inflammation and fibrosis. As an example of these common
‘‘factors’’, an increased hepatic supply of FFAs in the face of
hepatic insulin resistance will favour increased mitochondrial
FFA b-oxidation and the subsequent generation of oxidative
stress. Oxidative stress, along with other FFA-induced mechan-
isms including lysosomal cathepsin release and endoplasmic
reticulum stress, leads to the transcription and release of pro-
inflammatory cytokines from hepatocytes, which will add to
the pro-inflammatory milieu resulting from adipose tissue
inflammation and further inhibit the release and actions of the
anti-steatotic, anti-inflammatory and anti-fibrotic adipocyto-
kine adiponectin. Potential non-inflammatory mechanisms of
fibrosis in NAFLD include the direct pro-fibrotic effects of
leptin, insulin, norepineprine and angiotensin, all released in
increased amounts either from adipose tissue in obesity or, in
the case of insulin, by the pancreas in response to obesity-
related insulin resistance.
NUTRITION AND EXERCISE IN PATIENTS WITH NAFLD
The dietary and exercise habits of patients with NAFLD vary
based on ethnicity, geography and culture. However, perhaps
not surprisingly, available data consistently show that energy
intake is significantly higher in patients with NAFLD than in
individuals with no evidence of fatty liver.41 In the USA, high-
fructose corn syrup ingestion has increased dramatically over
the past 20 years42 and may contribute to the underlying
dysregulation in energy metabolism seen in NAFLD patients.
High-fructose diets in humans are associated with increased
energy intake, weight gain, increased fat mass and increased
blood pressure after only 10 weeks.43 They have also been
associated with increased hepatic DNL, hypertriglyceridaemia
and the development of hepatic insulin resistance.44 Animal
data have shown that these processes are probably the result of
fructose-mediated leptin resistance resulting in decreased
hepatic fatty acid oxidation via reduced leptin-mediated
PPARa activation.27 Musso et al studied the dietary intake of
25 NASH patients over a 7-day period, compared with 25 age-,
body mass index (BMI)- and gender-matched controls.45
Patients with NASH were found to have diets higher in
saturated fat and cholesterol and lower in polyunsaturated
fat, fibre and anti-oxidant vitamins C and E. Cortez-Pinto et al
also showed that NASH patients recalled diets higher in total
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and monounsaturated fat, as well as n-6 fatty acids.46 Animal
and in vitro data suggest that saturated and trans-unsaturated
FFAs increase insulin resistance while polyunsaturated FFAs
exert the opposite effect.47 Polyunsaturated FFAs may also be
directly anti-steatotic via inhibiting the abundance and DNA
binding activity of SREBP-1.48 Consistent with the activation of
ChREBP by glucose, two studies have recently reported an
association between dietary carbohydrate content and NAFLD
severity.8 49
In addition to poor dietary habits, lack of physical exercise
adversely impacts metabolic profiles significantly. Physical
inactivity is associated with increased body weight, central
adiposity and insulin resistance,50 and increased risk of
metabolic syndrome,51 NAFLD52 and severity of NASH.8 Many
of these effects may be mediated by low levels of AMPK
activation.30
DIETARY MODIFICATIONS FOR NAFLD
The primary problem in the majority of patients with NAFLD is
overweight or obesity and underlying insulin resistance. It
therefore seems logical that dietary advice would form the
cornerstone of therapy for these patients. From the above
discussion, diet-induced weight loss would be expected to have
a number of inter-related beneficial effects on NAFLD broadly
related to (1) reduced hepatic FFA supply; (2) improved insulin
sensitivity; and (3) reduced adipose tissue inflammation
(table 1). Unfortunately, large, prospective, randomised clinical
trials powered appropriately for histopathological end-points
are lacking. Rather, several small, uncontrolled, pilot trials
utilising differing caloric restriction regimens and combinations
of carbohydrate, protein and lipid have been performed,
reporting on a wide variety of histological and non-histological
end-points (table 2).
General caloric restriction
One of the first prospective studies to assess the effect of diet-
induced weight loss on liver pathology was performed in 1970
by Drenick et al.53 In this trial, three different weight loss
regimens were evaluated in 41 severely obese patients. The
majority of patients were treated with either prolonged fasting
or a 500 kcal/day diet. Patients lost a mean of 40.9 kg during
prolonged fasting for a mean of 71 days and 59.5 kg over an
average of 5 months in the low calorie arm. Repeat liver
biopsies showed improvement in hepatic steatosis. In 14
patients who were able to maintain the weight loss for an
average of 17 months, another biopsy was performed which
showed normalisation of histology in nine patients and
minimal abnormalities in the remaining five. A subsequent
small retrospective cohort of obese patients demonstrated that
a 10% weight reduction achieved on a 600–800 kcal/day diet for
a mean of 16 months resulted in improvement in liver enzymes
and hepatosplenomegaly; however, no follow-up liver biopsies
were performed.54
Specific macronutrient restriction
The dual role of lipid and carbohydrate as both providers of
substrates for hepatic lipid synthesis and activators of SREBP-1
and ChREBP transcription factors has prompted studies
examining their specific restriction in combination with
calorie-restricted diets in patients with NAFLD. The effect of a
low-fat (3%) reduced-calorie (daily intake 1200 kcal/day) diet
was studied by Petersen et al in eight patients with NAFLD.55 An
average 8% weight loss was associated with an 81% reduction
in intrahepatic lipid content as measured by magnetic
resonance proton spectroscopy (MRS). Whole-body insulin
sensitivity also improved, and hepatic triglyceride content,
fasting plasma glucose and total cholesterol were significantly
reduced. Utilising deuterated glucose, the authors demonstrate
that improvement in whole-body insulin sensitivity was
predominantly due to improved hepatic insulin responsiveness.
Westerbacka et al examined the effect of an isocaloric, low-fat
(16%) diet followed by an isocaloric high-fat (56%) diet on
hepatic lipid content determined by MRS, in a 2-week crossover
study in 10 obese non-diabetic women.56 The low-fat diet led to
a 20% decrease in hepatic lipid content which was followed by a
35% increase on the high-fat diet. Reports that low-carbohy-
drate, ketogenic diets (,20 g/day) are associated with a greater
weight loss and a better lipid profile than low-fat diets57 have
prompted a recent pilot trial of 6 months on a low-carbohydrate
diet in five obese NAFLD patients.58 A mean weight reduction of
12.8 kg was associated with a significant improvement in
hepatic steatosis and inflammation, and a trend towards an
improvement in fibrosis. As yet, only one dietary study has
specifically targeted patients with biopsy-proven NASH.59 In
this open label study, 16 NASH patients were placed on a diet of
40–45% complex carbohydrate/fibre, 35–40% fat (mainly mono-
or polyunsaturated fat) and 15–20% protein for 12 months,
aimed at weight reduction and improved insulin sensitivity. Of
the 15 patients who underwent repeat biopsies, nine had
improved histology and six remained stable. The improved
patients lost significantly more weight (7%) than the stable
patients.
Diet plus weight-reducing pharmacotherapy
Despite these encouraging data that diet-induced weight loss
may be beneficial for patients with NAFLD, the majority of
patients have difficulty achieving and maintaining weight loss.
Accordingly, pharmacological agents to augment dietary advice
have begun to be evaluated as therapy for patients with NAFLD.
Orlistat, an oral inhibitor of gastric lipases, blocks the
absorption of approximately 30% of dietary triglycerides. Early
data, in the form of a case series, showed that orlistat 120 mg
three times daily, in association with a low-fat diet, induced
Table 1 Potential beneficial effect of diet-induced weight
loss on non-alcoholic fatty liver disease
Main effect Result
Reduced hepatic FFA supply Q TAG synthesis
Q Hepatic insulin resistance
Q Hepatic glucose output
Q ROS generation
Q Hepatocyte inflammation
Improved extrahepatic insulin
sensitivity
Q De novo lipogenesis (QSREBP-1)
R reduced circulating insulin levels q VLDL export
Q Fibrosis
Q Adipose tissue inflammation Q Pro-inflammatory cytokines
q Leptin sensitivity (QSOCS-1)
q Adiponectin
FFA, free fatty acid; ROS, reactive oxygen species; SOCS, suppressor of
cytokine signalling; SREBP, sterol regulatory element-binding protein; TAG,
triacylglycerol;VLDL, very low-density lipoprotein.
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weight loss of 10–19 kg over a 6–12 month period and was
associated with a significant improvement in serum amino-
transferases and hepatic steatosis, inflammation and fibrosis.60
This report was followed by an open label trial of orlistat
120 mg three times daily plus a low-fat diet in 10 obese patients
with biopsy-proven NASH. The mean weight loss was 10.3 kg.
Significant improvements in BMI, haemoglobin A1C, serum
alanine aminotransferase (ALT) and aspartate aminotransfer-
ase (AST) were seen. Histopathological improvement in fibrosis
was found in three of five patients who were able to lose at least
10% of their body weight.61
More rigorous controlled trials with orlistat have since been
published. Zelber-Sagi et al studied the effects of orlistat in 52
patients randomised to receive placebo or orlistat 120 mg three
times daily for 6 months.62 Both groups were prescribed a low-
energy diet consisting of 104.5 kJ/day and encouraged to walk
for 40 min, 3–4 times weekly. Among the 44 patients who
completed the study, BMI was significantly reduced, with no
difference found between groups. The mean weight loss was 8%
in the orlistat group and 6% in the placebo group. Serum ALT
was reduced significantly in both groups, with a greater
decrease in the orlistat group. However, utilising ultrasound
assessment of hepatic steatosis, reversal of steatosis was seen
only in the orlistat group. Similar findings have recently been
reported from a second randomised controlled trial of orlistat in
50 overweight, biopsy-proven NASH patients treated with a
1400 kcal/day diet or a similar diet plus orlistat 120 mg three
times daily for 9 months.63 Of the 37 patients who have
completed the trial, a mean weight loss of 8.2 and 6% was seen
for the orlistat and diet alone group, respectively. Both groups
had similar improvements in steatosis, necroinflammation,
ballooning and NAFLD activity score (NAS) on follow-up
biopsy. When all patients from both groups losing >9% of body
weight (n = 14) were compared with those failing to achieve
this amount of weight reduction, greater improvements in
insulin resistance, AST, adiponectin, steatosis, inflammation
and NAS were seen in the .9% group. However, no improve-
ment in fibrosis was shown. While confirming the benefits of
diet-induced weight loss on NAFLD, these two studies show
that orlistat does not significantly enhance weight loss induced
by a hypocaloric diet, a finding corroborated by a recent Finnish
study in obese women.64
Intensity of weight loss
Data from some early studies suggested that too rapid a weight
loss may worsen the histopathology of patients with NAFLD.
Table 2 Effects of diet on metabolic parameters and hepatic steatosis
n Year
Total
calories/day % carbohydrate % fat % protein Study duration Weight loss
F/U
liver bx Results
Diet-NAFLD
Drenick et al52 41 1970 (1) total starvation
(mean 71 days)
NA NA NA 2.5–5 months Fasting:
40.9 kg
Yes Improved steatosis
(2) 500 kcal/day
(average 5 months)
Low-calorie
diet:
59.5 kg(3) JI bypass or
shunt
Palmer et al53 39 1990 600–800 NA NA NA Mean
16 months
17/39 pts
lost >10%
body weight
No Improved liver
enzymes, decreased
hepatosplenomegaly
Tiikkainen et al63 47 2004 600–800 50 30 20 3–6 months 8% No Insulin sensitivity,
intra-abdominal fat
and subcutaneous fat
decreased
significantly
Westerbacka
et al55
10 2005 Isocaloric 61 16 19 2 weeks 1 kg No Decreased fasting
serum insulin and
20% decrease in liver
fat by MRS
Peterson et al54 8 2005 1200 50 3 42 3–12 weeks 8% No Improved liver fat
81% by MRS
Tamura et al77 7 2005 27.9 kcal/kg/day 60 25 15 2 weeks NA No Improved liver fat
27% by MRS
Yancy et al56 45 2004 Not mentioned 8 68 26 6 months 12.9% No Not assessed
Yancy et al56 60 2004 Not mentioned 52 29 19 6 months 6.7% No Not assessed
Tendler et al57 5 2007 Not mentioned ,20 NA NA 6 months 12.8 kg Yes Improved steatosis
and inflammation
Diet-NASH
Huang et al58 15 2005 Not mentioned 40–45 35–40 15–20 12 months 7% in 9 pts
with
improved
histology
Yes Improved total NASH
score and steatosis
Diet + pharmacotherapy-NASH
Harrison et al60 10 2004 1400 NA NA NA 6 months 10.3 kg Yes Improved BMI,
HgbA1C, ALT, AST,
steatosis (6/10),
fibrosis (3/10)
Harrison et al62 37 2007 1400 NA NA NA 9 months 8 vs 6.2% Yes Improved steatosis,
inflammation, NASH
activity score
ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; HgbA1C; haemoglobin A1C; JI, jejuno-ileal; F/U liver bx, follow-up liver
biopsy; MRS, magnetic resonance proton spectroscopy; NA, not available; NAFLD, non-alcoholic fatty liver disease; NASH, non-alcoholic steatosis; pts, patients.
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Anderson et al evaluated the effects of a 388 kcal/day diet on 41
severely obese patients who lost a median of 34 kg over about
9 months.65 While steatosis significantly improved, 24% devel-
oped slight portal inflammation or slight fibrosis. No patients
losing ,1.6 kg/week had a worsening of fibrosis. This, along
with early bariatric surgery data demonstrating an increase in
inflammation following a mean of 32 kg weight loss,66 led some
investigators to advocate slow and mild to moderate weight
reduction for patients with NAFLD. More recent longer term
follow-up data from bariatric surgery studies have, however,
largely allayed these concerns,67–69 suggesting that the earlier
reports may have been attributable either to poor nutritional
support in these patients or to a transient histopathological
phenomenon occurring en route to resolution of NAFLD.
Taken together, these data demonstrate that diet-induced
weight loss approaching 10% of body weight is efficacious in
improving the metabolic parameters associated with NAFLD,
including lipid profiles and insulin resistance, as well as serum
aminotransferases, and, more importantly, the histopathologi-
cal characteristics of NASH including steatosis and necroin-
flammation. Further study is necessary to determine if weight
loss over a longer period of time equates to improvement in
fibrosis in patients with NASH. Additionally, no consensus has
been reached as yet on the most appropriate nutrient balance in
diets for NAFLD patients. A low processed carbohydrate diet
may achieve a more rapid weight loss, but this effect is probably
mitigated in the long term.70 To date no adjunctive weight-
reducing pharmacological therapies have, as yet, been shown to
be of any benefit.
EFFECT OF EXERCISE ALONE ON OBESITY, VISCERAL
FAT AND INSULIN RESISTANCE
Exercise physiology and the salutatory effects on weight loss,
fat reduction and insulin sensitivity have been described in
great detail. These beneficial effects are now considered to
reflect, at least in part, the effect of exercise on the activation of
AMPK. In obese non-diabetics, exercise has been shown to
reduce the risk of developing diabetes mellitus by up to 46%.71
Physical training, consisting of 20 min cycling or running,
20 min swimming at submaximal heart rate, followed by
20 min of warm up/cool down three times per week for
4 weeks, resulted in a significant reduction in body weight and
percentage body fat, and this was associated with improved
whole-body glucose uptake, decreased fasting insulin concen-
trations and increased circulating adiponectin and mRNA
expression in muscle. Among patients with type 2 diabetes
mellitus, increasing exercise led to a reduction in fasting
plasma glucose.72
The intensity of exercise needed to show improvement in
metabolic profiles has been studied by several investigators.
O’Donovan and colleagues evaluated the effects of 24 weeks of
moderate intensity exercise, defined as cycling three times
weekly at 60% VO2max to burn 400 kcal, versus high-intensity
exercise, defined as cycling three times weekly at 80% VO2max to
burn 400 kcal, versus no exercise, on insulin sensitivity,
triglycerides and glucose concentration.73 Training at 60%
VO2max was as effective as training at 80% VO2max when 400
kcal were expended per session, suggesting that moderate
exercise, expending 400 kcal per session, three times per week
is sufficient to improve insulin sensitivity. The overall energy
expenditure achieved per work-out session appears to be more
important than the intensity of the exercise. This is supported
by two recent studies performed in obese patients.74 75 Daily
exercise for 12 weeks, performed at not greater than 70%
VO2max (,80% maximum heart rate) on a treadmill to achieve
700 kcal energy expenditure (,60 min) resulted in an 8% body
weight loss and was associated with significant reductions in
abdominal obesity, visceral fat, waist circumference and insulin
resistance.74 Furthermore, this study showed that exercise
without weight loss also reduced both abdominal and visceral
fat. O’Leary et al also demonstrated that daily aerobic exercise
for 50–60 min, starting at 60–65% maximum heart rate and
increasing to 80–85% maximum heart rate (,70% Vo2max) over
4 weeks improved visceral fat content and this correlated with
improved glucose metabolism and loss of insulin resistance.75
These encouraging results were seen with only a 3% weight loss
over this time period.
The effects of aerobic versus restrictive exercise have also
been debated. A recent Turkish study examined the effects of
aerobic exercise, defined as walking briskly for 15 min and
exercising on a stationary bicycle for 12–15 min three times per
week the first month, exercising 20–30 min four times per
week the second month, and 30–45 min five times per week the
third month, in a group of 20 obese women compared with a
restrictive exercise utilising a stationary exercise unit in a
similar group of women over a 3-month period.76 While
improvement in BMI, fasting glucose and post-prandial glucose
were seen in both groups, reduced fat mass (as measured by
bioelectric impedence), decreased low-density lipoprotein and
insulin resistance were seen only in the aerobic exercise group.
In another study in 39 older obese men, aerobic or restrictive
exercise training 3 days per week for 6 months resulted in
similar improvement in whole-body glucose disposal.77
EFFECT OF EXERCISE PLUS DIET ON OBESITY,
VISCERAL FAT AND INSULIN RESISTANCE
The combination of diet and exercise appears to have a
synergistic beneficial effect on metabolic profiles. Weight loss
of >5% body weight achieved with diet and exercise has been
associated with a 59% reduction in the odds of developing
metabolic syndrome and increasing to 83% in patients losing
>10% of body weight.78 Tamura et al randomised 14 type 2
diabetic patients to either a 27.9 kcal/kg/day diet or a similar
diet plus exercise (walking 2–3 times/day for 30 min, 5–6 days
per week) for 2 weeks.79 Diet plus exercise resulted in improved
muscle insulin sensitivity as measured by a decrease in
intramyocellular lipid content and improved glucose infusion
rates, an effect not seen with diet alone. However, both groups
decreased intrahepatic lipid concentrations by 27%. When
exercise, either aerobic or restrictive, was added to a low-
calorie diet in obese men, insulin levels obtained via an oral
glucose tolerance test (OGTT) were approximately 2-fold better
than with diet alone.80 Data from the Diabetes Prevention
Program in the USA extended these findings, showing that a
low-calorie, low-fat diet with moderate physical activity such as
brisk walking for 150 min per week reduced the incidence of
diabetes by 58%.81 Importantly, this reduced incidence of
diabetes was significantly better than that achieved with the
insulin-sensitising medication metformin.
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EFFECT OF EXERCISE PLUS DIET ON NAFLD
A logical approach to improving the histopathological changes
seen in NAFLD and NASH, based on data detailed in this
review, would be lifestyle modifications that combine an
exercise programme with a tailored dietary regimen (table 3).
Animal data demonstrate that exercise training started
simultaneously with a high-fat diet prevents the development
of hepatic steatosis.82 A recent study by Baba et al evaluated 65
patients with NAFLD over a minimum of 3 months who were
placed on an aerobic exercise regimen and a specific diet.83 The
exercise regimen consisted of brisk walking, jogging or
rhythmic aerobic exercises for a minimum of 45 min, 5 days
per week, to achieve a target heart rate of 60–70% of their
maximal heart rate. The dietary regimen was predicated on a
total of 25 kcal/kg per day containing 60% carbohydrate, 20%
fat, 20% protein and 200 mg of cholesterol. A total of 44
patients complied with the exercise programme and were
included in the analysis. There was a significant improvement
in BMI, waist circumference, waist to hip ratio and serum
aminotransferases in the patients adherent to the diet and
exercise regimen. Interestingly, those patients who exercised
and did not lose weight still had a significant improvement in
their aminotransferase levels. Ultimately, a 4–4.5% decrease in
weight resulted in a 50% reduction in serum ALT. Others have
demonstrated that a combination of diet and exercise, leading
to an approximate 5% weight loss over 3 months, is associated
with improved serum ALT and AST.84 A similar amount of
weight loss was associated with a 3.6-fold increased probability
of normalising serum ALT in a large Japanese longitudinal
cohort study. In this study, patients who were able to maintain
their 5% weight loss had a 4.6-fold increased likelihood of
maintaining a normal ALT.85 Reductions in subcutaneous and
intra-abdominal fat have also been shown with 4% body weight
loss when diet and exercise regimens are combined.86
Two studies have assessed the effects of diet and exercise on
histopathology in patients with NAFLD.87 88 Ueno et al demon-
strated that a decrease in BMI of 3 points over a 3-month period
improved hepatic steatosis.87 Hickman et al subsequently
showed that steatosis and fibrosis improved in a small group
of NASH patients who lost approximately 4% of their body
weight over a 3-month period.88
SUMMARY
Excessive foodstuffs, particularly in the form of complex
carbohydrates, increased fructose consumption and saturated
fats, combined with a sedentary lifestyle have contributed to
the epidemic of obesity, dysregulated metabolism and NAFLD.
Our knowledge of the pathological consequences of poor
dietary choices and lack of adequate exercise on adipose tissue,
skeletal muscle and the liver is improving, and this will help in
establishing more specific guidelines for the proper nutrient
intake and exercise regimens that will improve underlying
metabolic pathways and ultimately decrease the incidence and
severity of NAFLD. For now it seems that diets aimed at
reducing total daily energy intake, based on either a low
processed carbohydrate, or low-fat macronutrient platform,
aimed at achieving about a 10% weight reduction, will improve
both metabolic and histopathological abnormalities in a diverse
group of NAFLD patients. Moderate exercise, preferably a
combination of aerobic and restrictive, performed 3–4 times per
week, expending about 400 calories each time seems adequate
to augment improvement in the metabolic profiles of patients
with NAFLD.
More rigorous, controlled studies, of longer duration and
defined histopathological end-points comparing diet alone,
exercise alone and diet plus exercise are needed before better,
evidence-based lifestyle modification guidelines can be estab-
lished, since several questions remain unanswered. Does
lifestyle modification work equally well in men versus women?
Do younger patients respond better than older patients to
lifestyle modification? Is there a diversity of response among
various ethnic groups or in patients with fatty liver alone
compared with patients with more progressive disease? Do
diabetic patients with NAFLD have a better histopathological
response to lifestyle modification than insulin-resistant
patients without diabetes and, if so, does the same amount of
weight loss equate to histopathological improvement, or do
these patients need to lose more or less weight, or simply need
to exercise more? Finally, are there different lifestyle modifica-
tion approaches, i.e. diet alone versus diet and aerobic exercise,
that work better for different patient populations?
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Answer
For questions see page 1754.
Differential diagnosis of gastric polypoid lesions include
fundic gland polyposis, hyperplastic polyp, adenoma or
adenocarcinoma, raised erosions, non-Hodgkin’s lymphoma,
mucosal associated lymphoid tumour (MALToma) and meta-
static cancers. The fundic gland polyp usually has the same
colour as the gastric mucosa and is usually located in the
fundus and high body. Hyperplastic polyp could present as
sessile to pedunculated shape. Gastric lymphoma could present
as different shapes of varying sizes in any portion of the
stomach. Our first impression of the gastric polypoid lesions in
this case was metastatic cancer and the pathology results from
the biopsy surprised us.
The pathology results revealed atypical cells between the
gastric foveolae and gastric glands. These cells had angulated
nuclei and small to moderate amounts of eosinophilic
cytoplasm. Some had multiple nucleoli. Immunohistochemical
staining showed these cells were negative for cytokeratin and
positive for factor VIII. This histological picture and immuno-
histochemical staining suggested dysplastic megakaryocytes
(see arrow, fig 2). Scanty myeloblasts, eosinophilic myelocytes,
and some band and segment forms of white blood cells were
noted. According to the above findings, the patient was
suffering from the rare condition of extramedullary haemato-
poiesis in the stomach (fig 2). In patients with haematological
disorders, this characteristic endoscopic picture should raise a
suspicion of extramedullary haematopoiesis in the stomach. To
our knowledge, after extensively review, there have been only
three reported cases of gastric extramedullary haematopoiesis
in the English medical literature.1 2
doi: 10.1136/gut.2006.110130a
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